Goserelin Phase 2 Trial NCT00544830 Status Updated to Active, Not Recruiting

On October 28, 2026, a clinical trial update was recorded for the study "Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer," registered as NCT00544830. The trial involves goserelin, an approved hormone therapy agent, used alongside intensity-modulated radiation therapy in patients with metastatic prostate cancer. According to the registry, the study is a Phase 2 trial. Its current status is listed as active, not recruiting, meaning the trial is ongoing but is no longer enrolling new participants. No results or outcome data were included in this update. The status change reflects the trial's progression stage as recorded in the registry entry as of the listed date. This brief reports only the status and phase information provided in the trial record and does not characterize any treatment effects, benefits, or risks associated with goserelin or the radiation therapy regimen used in the study. Readers interested in the broader context of this treatment combination should consult the full trial registry for additional protocol details. For more background on this compound, see the goserelin overview.